echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Gastroenterology H: Reducing the duration of use of Usnu monoantigen can improve the effectiveness of treatment for Crohn's disease

    Clin Gastroenterology H: Reducing the duration of use of Usnu monoantigen can improve the effectiveness of treatment for Crohn's disease

    • Last Update: 2021-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Although Usnu monoantigen has been recommended by the guidelines as a second-line biological agent for the treatment of Crohn's disease, there are still some patients who have a loss of response to Usnu monoantigen.
    90 milligrams of medication is used every eight weeks during using the single anti-maintenance treatment, this study aims to explore whether shortening the time interval between dosing may benefit the treatment of Crohn's disease.
    researchers used retrospective studies to assess the effectiveness of shortening the dose interval between usanu monoantigens, which collected data from 506 patients who received 90 mg of ussin monoantigens every 8 weeks.
    110 other patients initially received sub-skin injections of usanut 90 mg every 8 weeks, and then the interval was reduced to every 4 weeks.
    Bradshaw index (HBI) score before and after shortening dose intervals in the queue was applied to 78 patients (71%) and 60 patients with C-reactive protein (CRP) levels (55%).
    results showed that after the dose interval was shortened, the patient's median HBI was reduced from 4.5 to 3 (P-.002), the median CRP was reduced from 8 mg/L to 3 mg/L (P=.031), and the median fecal calcium-guard protein was reduced from 378?g/g to 157?g/g (P.57).
    in patients with HBI,4, CRP levels ≥5mg / dL, fecal calcium protein levels 250ug / g, or endoscopic evidence of disease activity before shortening the dose interval, after shortening the dose interval, 28% of patients received clinical remission (HBI score ≤4), 22% of patients returned to normal levels of CRP (-lt;5 mg/dL), 50% of fecal calcium protein levels decreased, and 36% had endoscopic remission.
    the study, researchers confirmed that reducing the interval between usanu monoantigens to four weeks for non-responsive CD patients at 90 mg per 8 weeks could improve clinical and biological indicators of disease activity.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.